Lines 220-223: Please clarify if and how the intensity of physical activities was included in the score assessing physical activity.
Lines 227-231: Please clarify how the number of comorbidities is a validated way to adjust for comorbidity and explain how/on what basis the variables for which the analyses were adjusted were selected.
Results: Lines 331-335: Please state in which table the effect estimates are listed.
Lines 338/339: Since the risk estimates were quite high (2.89 to 3.60) and because of consistency (in the preceding paragraphs this is done continously), you should mention the exact hazard ratio estimates here as well. Table 3 : For a better understanding it would be helpful if you state for which variables the analyses were adjusted for.
Discussion: Lines 376/377: "The link ... in people with dementia is well known, and is reflected in our analysis." However, your study collective consisted of cognitively impaired participants of which only 13% had a diagnosis of dementia (table 1) . Please clarify this aspect.
Line 383: "...indicates a potential class specific effect,..." I miss an explanation for this presumed effect. What could be the underlying pathway if it is not the anticholinergic effect, as the authors write in this paragraph?
Lines 408 to 416: How do you explain your findings? What could be the reason that you "observed the greatest risk" of mortality "in non-frail participants with polypharmacy" and not in frail participants?
Lines 440 to 445: "...our findings suggest that medication review ... should be a high priority for cognitively impaired patients..." Medication review was not the topic of research of the present study. Therefore, the conclusion does not appear to be justified by the results of this study. The same applies to the following sentence "...where possible careful deprescribing will help to improve quality of life and reduce adverse outcomes". Line 473: "Polypharmacy and hyper-polypharmacy increased risk of mortality..." Since this was an observational study (and not a randomized controlled study) I recommend a more cautious phrasing of the association.
Limitations:
The authors should consider taking into account effects and potential biases resulting from the prevalent user design of their study. 
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 1) …highlight, in the section on potential limitations, the lack of self-reported information on two common and clinically relevant conditions, i.e. CKD and heart failure. Both CKD and heart failure might potentially affect the study end-points, e.g. mortality.
In our analyses we were able to adjust for a range of cardiovascular and other comorbidities but were limited by the information collected as part of the CFAS 2 study. Unfortunately, heart failure and CKD were not specifically mentioned, although the effects of these may have been captured using the 'frailty' variable. In the context of polypharmacy, we recognise that all comorbidity is relevant as a potential confounder, and so we have highlighted the lack of self-reported information on these clinically relevant conditions in the limitations section.
"In particular we could not control for every possible indication for medications contributing to polypharmacy owing to the limitations of the available data. For example CFAS II did not record data on chronic kidney disease or heart failure that are also linked to medication use and mortality. However controlling for of the frailty variables, which reflect general health status, did not attenuate the associations between polypharmacy and death."
Reviewer: 2
2) The relationship between PPI intake and mortality is certainly an important field of research. However, it is not explained to what extent this drug class poses a particularly high risk to cognitively impaired patients. In my opinion, PPIs are a separate issue and should be treated separately (in a patient population that is not exclusively cognitively impaired, if possible). The authors might want to consider excluding the PPIs from this paper and discussing them in a separate paper instead. Otherwise, according to the emphasis on PPIs in the abstract and the introduction, the association between PPIS and mortality should be mentioned in the results and the discussion as well.
We agree that the ongoing research around PPI intake and adverse outcomes, including mortality is an important area that we have been able to go some way to further the understanding around this. We do however acknowledge that the presentation of these results was not adequate and we have now included the following in the results and discussion sections:
Included in the results section:
"No significant effect on survival was seen for any other central nervous system acting PIM (table 2) . Additionally, there was no significant effect on survival associated with PPI use (HR 1.16 95% CI 0.95-1.42)… …After adjusting for confounders, no significant association was evident in the remaining central nervous system acting PIM or PPIs (see Table 2 )."
The following has been added into the discussion:
We found no evidence for an association between PPI use and mortality in this cognitively impaired population. PPIs are highly prevalent and are often overused without appropriate indication [27, 51, 52] . For people with comorbidities and polypharmacy who are taking PPIs on a long-term and potentially inappropriate basis there may also be a risk of drug-drug interactions which can lead to a range of adverse effects. Deprescribing inappropriate PPIs among older people is considered a priority [40] and while we did not find PPI use was associated with survival, there is building evidence suggesting PPIs are associated with other clinically important adverse effects including Clostridium difficile and increased risk of fractures [27, 53] .
Methods:
Lines 137/138:
3) I could not follow the argumentation why registration with a single primary care provider allows representative sampling. Please clarify.
In the UK under the National Health Service, each person is typically registered with exactly one primary care provider, and each practice is limited to a specific area. Hence GP lists provide a good enumeration of local populations, and sampling from patient lists in primary care practices is an excellent way to obtain a representative sample of the population of a geographic area of the UK.
We have included clarification on this in the methods section:
"In short, participants were randomly sampled from primary care lists within three geographic centres representing urban and rural areas (Nottingham, Cambridgeshire and Newcastle) between 2008 and 2011. In England, the vast majority of people are registered with a single primary care provider, and so primary care patient lists form sampling frames that are close to enumerations of the populations of specific geographic areas. Approximately 2500 participants were recruited from each centre. All participants were 65 years of age at baseline and were interviewed in their usual place of residence, whether this was their own home or a long-term care facility, by a trained interviewer." Lines 180/181: 4) Please explain why you excluded PIMs from the polypharmacy variable.
While we recognise that the use of PIMs would be contributory to polypharmacy, we wanted to be sure that the potential risk associated with polypharmacy could be identified as independent of the harm that may have been associated with PIM prescriptions. Including PIM in the polypharmacy variable would have made this impossible.
Second, we wanted to ensure the exposure variables included were mutually exclusive to reduce the possibility of bias associated with the medications of interest being included in the linear models twice, had the polypharmacy variable included PIMs as well as independently.
We have provided this clarification in the methods section of the paper. "Total number of prescribed and over-the-counter medications was ascertained from medication lists collated during interviews. This number excluded the specific PIMs described above, to allow for mutually exclusive exposures comparing PIMs to polypharmacy and to understand the effect of polypharmacy on mortality, independent of PIM use.." As mentioned in the previous response, and in common with the approach taken in many epidemiologic studies, we operationalised a frailty measure based on available data rather than by specifying questions ourselves. The question on weight loss was asked in this way (loss of 10lb over 6 months) during the CFAS interview.
We acknowledge that this is a variation on the Fried et al (2001) definition of unintentional weight loss associated with frailty. Note however that Fried et al constructed their initial measure of frailty opportunistically from an existing dataset and there is likely to be no specific reason for them to have chosen a 1 year time window for this question except for the availability of the data.
We have added some extra detail to the manuscript in the limitation section to elaborate on this difference.
We could not operationalise phenotypic frailty measures exactly as per their original definition [43], although our measures did independently predict mortality in this sample and our approach to measuring frailty using existing data is similar to that taken by many other epidemiologic studies.
Lines 220-223: 7) Please clarify if and how the intensity of physical activities was included in the score assessing physical activity.
The intensity of the activity was ascertained from a series of questions around physical activity that asked about the amount of time spent doing vigorous, moderate or mildly energetic activities. An initial question asked the participants if they took part in vigorous activity, if the participant answered yes to this question they were asked a series of questions regarding the amount of time spent doing specific activities including running, swimming or cycling, for example. When asked about a specific activity, the participants identified the amount of time spent doing these activities and could be categorised as 'no', 'more than once a week', 'once a week', 'one to three times a month' or 'hardly ever or never'. To operationalise the frailty criterion, time spent doing each activity was scored. For each activity, participants answering either 'no', 'one to three times a month', or 'hardly ever or never', were allocated a score of 1. Participants answering, 'more than once a week', or 'once a week' were allocated a score of 0. The total score across each of the specific activities was summed to create a continuous variable, with higher scores indicating less reported physical activity. The amount of time spent doing these activities was used as the marker of intensity.
We have clarified this by now also including the following information in the paper. "This was scored based on responses to a series of questions about time spent in specific activities, including for example swimming, jogging, walking, gardening and housework (see supplementary file for a full list). A score of 1 was allocated for each activity if a participant reported doing an activity hardly ever or never, less than three times a month or not engaging in the activity at all, and 0 if more frequently. The scores across activities were summed to create a continuous variable, where higher scores indicated less activity. " 8) Please clarify how the number of comorbidities is a validated way to adjust for comorbidity and explain how/on what basis the variables for which the analyses were adjusted were selected.
Previous studies have validated the number of comorbidities as a good predictor of mortality ((cstatistic 0.901 95% CI 0.898, 0.904) (eg Quail et al 2011). However, we acknowledge the limitation of this compare to controlling for each comorbidity separately and so we have now conducted an additional sensitivity analysis test the effect of controlling for comorbidity as a cumulative variable. We have estimated our full multivariate Cox regression model including the comorbidities as individual covariates and compared these model estimates with the model including the cumulative comorbidity variable. The results (below) showed little change in the model estimates when individual comorbidities were included compared with the number of comorbidities (see appendix 3 in the supplementary material). We have discussed this analysis in the manuscript as a sensitivity analysis in both the methods and results section and included it in the supplementary material. We have now included that the table that the effect estimates of the univariate analyses of the pre-frail and frail mortality risks can be found. The estimates can be found in Table 2 , as now included in the text as follows:
"Being frail and pre-frail remained significantly associated with mortality in the fully adjusted model (frail HR=1.90 95% CI=1.32 -2.71, pre-frail HR=1.56, 95% CI=1.10-2.20) (see Table 2 )."
Lines 338/339: 10) Since the risk estimates were quite high (2.89 to 3.60) and because of consistency (in the preceding paragraphs this is done continuously), you should mention the exact hazard ratio estimates here as well.
We have added the risk estimates in as follows: "The hazard ratio associated antipsychotic use among non-frail users was 3.60 (95% CI 0.40-31.99), was 2.89 (95% CI 1.26-6.66) in pre-frail and was 3.34 (95% CI 1.37-8.12) among the frail" Table 3: 11) For a better understanding it would be helpful if you state for which variables the analyses were adjusted for.
We have included in the table caption the variables that the analyses were adjusted for as follows:
"…adjusted for age, gender, MMSE score, care home residence and comorbidities." Discussion:
Lines 376/377: 12) "The link ... in people with dementia is well known, and is reflected in our analysis." However, your study collective consisted of cognitively impaired participants of which only 13% had a diagnosis of dementia (table 1) . Please clarify this aspect.
Thank you for highlighting this and we have made the following amendments to the paper to reflect, as you highlight, the primary inclusion of participants with cognitive impairment. Of the eleven participants taking antipsychotics who died, only one person had a dementia diagnosis at CFAS II interview. We have added the following into the discussion.
The link between antipsychotic medication and mortality in people with dementia is well known [49] and our result extends this finding to a broader group with cognitive impairment.
Line 383: 13) "...indicates a potential class specific effect,..." I miss an explanation for this presumed effect. What could be the underlying pathway if it is not the anticholinergic effect, as the authors write in this paragraph?
As in our discussion, since antipsychotics are the only class that we find to be linked with mortality it could be a pathway specific to antipsychotics and not to anticholinergics in general that drives an apparent association between anticholinergics and mortality in other studies.
Lines 408 to 416: 14) How do you explain your findings? What could be the reason that you "observed the greatest risk" of mortality "in non-frail participants with polypharmacy" and not in frail participants?
We expect that this may be associated with varying levels of underlying risk of mortality. In the less frail groups, the baseline risk of mortality associated with other causes is lower but if polypharmacy cause a similar increase in absolute risk across frailty groups a lower corresponding relative risk would be seen in frailer participants. Whilst we want to avoid over-speculation, this variation might also be explained by different types of drugs being used in the frail and non-frail participants. With this in mind, future studies would benefit from understanding the different drug classes that are contributing to polypharmacy in older adults to identify common classes of drugs and whether there is a difference in the types of drugs across levels of frailty. We have slightly reworded this section of the discussion to make this clearer.
Lines 440 to 445: 15) "...our findings suggest that medication review ... should be a high priority for cognitively impaired patients..." Medication review was not the topic of research of the present study. Therefore, the conclusion does not appear to be justified by the results of this study.
Thank you, this was over-stated. We have removed reference to medication review from the implications section.
16) The same applies to the following sentence "...where possible careful deprescribing will help to improve quality of life and reduce adverse outcomes".
As above, we have removed this comment.
Line 473: 17) "Polypharmacy and hyper-polypharmacy increased risk of mortality..." Since this was an observational study (and not a randomized controlled study) I recommend a more cautious phrasing of the association.
We agree than a more cautious phrasing of the association is necessary. We have made the following change:
"Polypharmacy and hyper-polypharmacy were associated with an increased risk of mortality" Limitations:
18) The authors should consider taking into account effects and potential biases resulting from the prevalent user design of their study.
We agree that there are likely to be differences between prevalent and new users of a medication. However estimating effects in prevalent users is particularly relevant in this patient group and for these specific medications where exposure may go back years or decades. We had previously included the limitation that our findings may not apply to new users, and have strengthened this as follows:
This suggests that much PIM use recorded in our study was 'prevalent use', reflecting long term use among a population who are stable on each medication, and so might not be applicable to those considering a new prescription of a PIM and who may be expected to be at higher initial risk. Thank you for taking the time to identify these errors. We have corrected these mistakes within the paper, as well as other minor changes.
